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Abstract
Background: The noble gas xenon is considered as a neuroprotective agent, but availability of the gas is limited.
Studies on neuroprotection with the abundant noble gases helium and argon demonstrated mixed results, and
data regarding neuroprotection after cardiac arrest are scant. We tested the hypothesis that administration of 50 %
helium or 50 % argon for 24 h after resuscitation from cardiac arrest improves clinical and histological outcome in
our 8 min rat cardiac arrest model.
Methods: Forty animals had cardiac arrest induced with intravenous potassium/esmolol and were randomized
to post-resuscitation ventilation with either helium/oxygen, argon/oxygen or air/oxygen for 24 h. Eight additional
animals without cardiac arrest served as reference, these animals were not randomized and not included into the
statistical analysis. Primary outcome was assessment of neuronal damage in histology of the region I of hippocampus
proper (CA1) from those animals surviving until day 5. Secondary outcome was evaluation of neurobehavior by daily
testing of a Neurodeficit Score (NDS), the Tape Removal Test (TRT), a simple vertical pole test (VPT) and the Open Field
Test (OFT). Because of the non-parametric distribution of the data, the histological assessments were compared with
the Kruskal–Wallis test. Treatment effect in repeated measured assessments was estimated with a linear regression with
clustered robust standard errors (SE), where normality is less important.
Results: Twenty-nine out of 40 rats survived until day 5 with significant initial deficits in neurobehavioral, but rapid
improvement within all groups randomized to cardiac arrest. There were no statistical significant differences between
groups neither in the histological nor in neurobehavioral assessment.
Conclusions: The replacement of air with either helium or argon in a 50:50 air/oxygen mixture for 24 h did
not improve histological or clinical outcome in rats subjected to 8 min of cardiac arrest.
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Background
Cardiac arrest is an important cause of global cerebral
ischemia and only a minority of resuscitated patients
survive in good neurological condition [1–3]. Neuronal
injury is not uniformly distributed, and follows a distinct
time course with delayed disintegration of neurons [4].
This late neuronal degeneration theoretically opens a
window of opportunity to mitigate the devastating effects
of ischemia on the brain. Although many substances af-
fecting neuronal inflammation have neuroprotective prop-
erties in in-vitro and animal experiments [5, 6], the only
neuroprotective measure known to have a profound effect
on survival and functional outcome after CA in humans is
temperature management [7–9].
The inert gas xenon is known for its anesthetic proper-
ties since 70 years [10], and it displays neuroprotective
effects in vitro and in different animal models of neuronal
injury [10–15]. The exact molecular mechanisms for neu-
roprotective properties of xenon are not fully understood
and probably multifactorial; xenon modulates neuroin-
flammation and apoptosis, it induces hypoxia-inducible
factor-1alpha (HIF-1alpha) it activates TREK-1 channels,
and modulates adenosine triphosphate (ATP)-sensitive
potassium channels (KATP channels) [10]. Unfortu-
nately, xenon is not readily available. The more ob-
tainable noble gases helium and argon have also
revealed similar properties [16]. In vitro models dem-
onstrated beneficial effects for helium regarding
neuron survival in traumatic brain injury [17]. Similar
effects are shown for argon in traumatic brain injury
[14, 18] and in addition in hypoxia [18, 19] but not
in stroke [20].
In vivo, helium reduces the ischemic burden in a com-
bined hypoxia/ligation model [21], but no animal or human
data exist to date regarding the effectiveness of helium neu-
roprotection after cardiac arrest. A recent trial with helium
treatment in patients after cardiac arrest suggests that this
treatment is safe and feasible in the clinical setting [22].
Regarding argon, animals studies have demonstrated bene-
ficial properties on neuroprotection in stroke [20, 23], in
neonatal asphyxia [21] and in cardiac arrest in rats [24–26]
and pigs [27]. In the aforementioned rat experiments, ani-
mals exposed to 40–70 % argon after cardiac arrest demon-
strated less neurologic dysfunction and less injury in
histopathological analysis, even after delayed argon expos-
ure. In the porcine experiments, the six animals subjected
to a 4 h treatment with 70 % argon displayed significantly
less neurological deficits, less increase in neuron-specific
enolase and less histological brain injury.
Based on these promising results, and given the theor-
etical benefits and potential implications in humans, our
objective was to investigate the effects of these gases in
our rat cardiac arrest model [28]. We hypothesized that
the inert gases helium and argon lessen neurological
damage after cardiac arrest in an 8 min cardiac arrest
model in rats. Neurological damage was defined clinically
and histologically. We focused on the hippocampus CA1
region which is considered the most vulnerable area of the
brain to hypoxia [29].
Methods
This animal study was approved by the Animal Care and
Experimentation Committee of the Canton of Bern (Nr
BE 6/13), Switzerland and followed the Swiss national
guidelines for the performance of animal experiments.
Forty-eight adult male Wistar rats (9–10 weeks old) were
obtained from a commercial breeder (Janvier Labs, Le
Genest-Saint-Isle, France) and housed at the central ani-
mal facilities of the University.
Randomisation/group assignment
Before anaesthesia, the rats were randomized to one of
the experimental groups (helium, argon, air) by drawing
concealed lots. Animals which did not survive surgery or
did not have a return of spontaneous circulation (ROSC)
were replaced immediately with an animal of the same
group. Eight non-ischemic sham animals were added to
the study to overview histology and performance in the
neurobehavioral tests after anesthesia and surgery only.
These animals required a different postoperative care
and were thus not randomized and were not included
into the statistics. Results of these animals are presented
but highlighted as not randomized.
All animals underwent the same anaesthesia and instru-
mentation procedures and, except the non-ischemic sham
animals, experienced cardiac arrest/resuscitation with a
standardized protocol [28, 30]. The postoperative proceed-
ings (including postoperative pain medication) were the
same in all groups except in the non-ischemic sham ani-
mals, which were weaned from mechanical ventilation
earlier. The groups were planned as following:
Group helium: 8-min cardiac arrest, treatment 24 h
with a mixture of 50 % helium in oxygen.
Group argon: 8-min cardiac arrest, treatment 24 h with
a mixture of 50 % argon in oxygen.
Group air: 8-min cardiac arrest, standard treatment
24 h with oxygen titrated to reach a 50 % oxygen in
nitrogen gas mix.
Cardiac arrest and resuscitation protocol
The model and detailed experimental procedures were
described elsewhere [28], here we provide the overview.
Anaesthesia was induced with sevoflurane and fentanyl,
then orotracheal intubation and mechanical ventilation,
followed by surgical insertion of a PE50 catheter into the
jugular vein and femoral artery. The animals were para-
lyzed with vecuronium and cardiac arrest initiated with a
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mixture of potassium and esmolol. After 8 min resuscita-
tion we started with manual chest compression (two
finger approach using the index and middle finger) at a
rate of 220 per minute guided by a metronome; and intra-
venous epinephrine and calcium. Ventilation was adapted
according to arterial blood gas analysis (aBGA) after 5 and
15 min post-return of spontaneous circulation (ROSC).
Fifteen minutes post ROSC, ventilation was switched to
the gas mixture according the group assignment and a
final blood gas analysis was performed at ROSC+ 60 min
before catheter removal and wound closure. Sevoflurane
was added at a minimal dose to avoid self-extubation and
the animals received fentanyl every hour for 3 h. 3.5 h post
ROSC buprenorphine was administered subcutaneously,
4 h post-ROSC the mechanical ventilation was weaned.
The non-ischemic sham animals had their wounds closed
after the ROSC +15 min blood gas analysis and were
weaned from mechanical ventilation thereafter, thus they
received buprenorphine only. The rational for this devi-
ation in the non-ischemic sham group is based on the
assumption that the higher amount of sevoflurane might
have a impact on apoptosis itself [31, 32], even though we
would not expect any neuronal damage in sham operated
animals.
After extubation, the animals were placed in a custom
constructed air-tight single cage on a heating pad for the
next 20 h. Argon and helium was purchased in cylinders
via hospital pharmacy (Carbagas Switzerland) and mixed
with oxygen from the wall outlet. The oxygen concentra-
tion in the delivered gas mix was monitored with the gas
module of the Datex S-5 anesthesia monitor (Datex
Ohmeda, now GE, Helsinki, Finland). The respective gas-
mix passed through a heat-exchanger and was maximally
moistured and entered the cage with 32 °C at a flow of
1.5 l/min. The animals had full access to water and food
in this special cage. Twenty-four hours after ROSC, the
animals returned to their standard cage with access to
water and food ad libitum.
Five days after cardiac arrest, the animals were eutha-
nized with an overdose of pentobarbital intraperitoneally
(150 mg/kg). Then the animal was transcardially perfused
via the left ventricle with 150 ml of buffered formalin 4 %
in phosphate-buffered saline (PBS) for subsequent de-
capitation and removal of the brain for dissection of
the hippocampus for final preservation.
Assessments
Determination of neuronal damage was performed on a
representative 10 μm section of the hippocampal cornus
ammoni 1 (CA1) segment using Fluoro-Jade B (FJB,
Millipore) staining. FJB staining allows the identification
of degenerating neurons [29]. Fluoro-Jade results were
expressed by normalizing the total amount of positive cells
by the length of the investigated CA1 segment.
Injury to the hippocampus was also determined by
histomorphometry of four representative sections of dorsal
(septal pole) CA1 slides stained with cresyl violet. The per-
centage of cells with apoptotic morphology (shrunken
appearance and condensed nucleus) was estimated in the
CA1 region by visual observation under a bright-field
microscope. Atrophy of the CA1 region, resulting from
neuronal loss, was determined using the software ImageJ
1.45 l (National Institutes of Health, USA, http://imagej.
nih.gov/ij). For this aim, the area of the CA1 subfield
stained by cresyl violet was determined with the software.
To correct for differences in the length the CA1 between
sections, normalization was performed by dividing the cal-
culated surface by the length of the structure, determined
at its border proximal to the dentate gyrus, hence provid-
ing an average breadth.
All histopathological evaluations were performed by
the same investigator, blinded to the clinical and treatment
data of the respective animal.
As secondary outcome we assessed general health and
neurological function daily from baseline (pre-arrest) until
day 5 using several tests: NDS [33] assessing general be-
haviour deficits (consciousness, respiration) as well as
cranial nerve, motor, sensory and coordination function
deficits. In addition, a simple VPT [34, 35] was performed,
assessing forelimb strength, ability to grasp and balance as
well as the TRT [36], which is considered a sensitive test
evaluating sensorimotor integration, originally used to
lateralize sensorimotor deficits and adopted and modified
to record the time period until removal of both tapes for
quantifying neuronal damage.
To determine general activity levels and exploration
habits the OFT was used [37]: the animals were placed
in the middle of the arena and allowed to freely move
for 4 min while being recorded. We analysed the footage,
mobility/immobility ratio, extern/intern ratio and the rears
(vertical activity).
Statistics
More than 50 % of the data were distributed non-
normal, as assessed by the Shapiro-Wilk test. Data are
presented as medians and interquartile ranges [IQR].
Histological assessments were compared with the non-
parametric Kruskal–Wallis test. For secondary outcomes,
we compared the baseline characteristics using non-
parametric statistics (Mann–Whitney U test, Kruskal–
Wallis test). Because of the non- parametric distribution
of the data, the treatment effect in repeated measured as-
sessments could not be examined with a mixed ANOVA.
We therefore used a linear regression with clustered robust
standard errors (SE), where normality is less important
(because of the robust SE). The time effect was assessed
with an additional fractional polynomial regression.
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As already outlined, the non-ischemic sham animals
were not randomized and thus not included in the main
analysis. We have included the non-ischemic sham ani-
mals in the tables to show reference values, and added
post-hoc non-parametric tests (Friedman, Wilcoxon) for
the non-randomized and randomized groups. These add-
itional values are printed in italics to indicate them as
non-randomized and post-hoc, and these values should be
interpreted cautiously.
A p < 0.05 was considered as significant. Standard calcu-
lations were performed using SigmaPlot/SigmaStat 12.5
(Systat Software GmbH, Erkrath, Germany), linear regres-
sion with robust clustered SE and fractional polynominal
regression was performed with STATA 13 (StataCorp;
College Station, TX, USA).
Results
Of the 40 animals which were randomized one animal
died due to surgical complications, and 39 animals en-
tered the cardiac arrest protocol. Of these 39 animals 31
reached a ROSC (82 %), one animal died 7 h post ROSC,
another one 4.5 days after ROSC and after initial recovery,
both animals were in the air group (Fig. 1).
Baseline characteristics of all animals in terms of haemo-
dynamics (heart rate, mean arterial pressure (MAP),
metabolics/respiration (glucose, lactate, pH, pO2, pCO2),
temperature and weight did not differ between groups
(Tables 1 and 2). Time to ROSC did not significantly differ
between the groups (helium 59 s [42–65], air 59 s [45–76]
and argon 70 s [55–83], p = 0.25).
There were no differences in the trends of haemo-
dynamics, metabolics/respiration, temperature or weight
between goups. The animals developed a significant lac-
tic acidosis, but without differences between the groups.
MAP increased after resuscitation, at 15 min the blood
pressure reached a minimum and then started to increase
towards baseline pressure again. Only heart rate tended to
increase more in the air group compared to the noble gas
groups (Table 1, p = 0.056).
The results of the TRT, the NDS and the VPT did not
differ between the groups (Table 2). In these tests the
animals demonstrate significant impairment on day one,
and start to recover until they reach baseline levels on
day 4–5 (TRT), or day 2 (NDS and VPT).
In the OFT, the resuscitated animals showed a de-
crease in exploratory behavior between day 4 and day 5,
but without significant differences between the groups
(Table 2).
In the histologic examinations substantial damage could
be found in the animals which suffered from cardiac arrest
compared to the non-randomized non-ischemic sham ani-
mals. FJB staining demonstrated an absence of neuronal
degeneration in the non-ischemic sham animals, but no
differences between groups in the resuscitated rats (details
Table 3 and Fig. 2). In the cresyl violet stained slides, no
cells with signs of ischemic damage could be seen in the
non-randomized non-ischemic sham animals, as assessed
by pyknotic cell counts. Compared to air/oxygen rats with
up to 80 % [IQR 61–93] destructed cells, the noble gas
treated animals trended to less damage (helium 53 %
[24–76], argon 59 % [44–86], p = 0.09, Table 3, Fig. 3).
The cell layer of the CA1 segment depicted atrophy
in the resuscitated animals as determined by a reduced
average breadth, but no differences between the noble
Fig. 1 Flow chart of the study. The non-ischemic sham animals were not randomized and were not subjected to cardiac arrest, therefore they
were not included into statistics
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Table 1 Hemodynamic data and blood gas analysis
Helium/oxygen Argon/oxygen Air/oxygen Kruskall - Wallis Non-ischemic sham
Mean Arterial Pressure (MAP)a [mmHg] Baseline (Before) 100 [86–114] 99 [90–108] 100 [82–118] p = 1.00 90 [79–92]
5 min 125 [115–137] 121 [109–138] 123 [109–129] 88 [78–102]
15 min 76 [62–94] 79 [77–92] 85 [69–100] 98 [87–105]
30 min 85 [65–98] 73 [68–86] 85 [66–93] NA
60 min 95 [82–97] 85 [67–101] 99 [83–111] NA
Friedman-Test p <0.001a <0.001a 0.004a 0.964
Linear regression with clustered robust SE p = 0.621
(Coef. helium: −1.93 CI −11.49 to 7.63; Coef. argon: −4.71 CI −14.70 to 5.28)
Time effect: fractional polynomial regression p < 0.001
Heart ratea [1 min−1] Baseline (Before) 300 [268–345] 340 [298–383] 360 [325–395] p = 0.10 300 [285–380]
5 min 300 [288–325] 290 [270–330] 320 [265–355] 320 [320–380]
15 min 300 [285–325] 310 [290–340] 290 [280–340] 360 [340–380]
30 min 360 [320–400] 320 [308–410] 395 [345–420] NA
60 min 340 [300–400] 340 [323–435] 420 [375–450] NA
Friedman-Test p 0.058 0.005a <0.001a 0.369
Linear regression with clustered robust SE p = 0.056
(Coef. helium: −30.3 CI −56.0 to −4.7; Coef. argon: −17.3 CI −50.1 to 15.5)
Time effect: fractional polynomial regression p < 0.001
Glucosea [mmol/l] Baseline (Before) 10.5 [8.9–11.6] 9.9 [8.8–10.9] 10.4 [8.4–11.1] p = 0.87 9.8 [8.7–11.2]
5 min 13.7 [13.4–14.5] 13.3 [11.1–16.0] 13.5 [13.1–15.6] 8.2 [7.5–10.2]
15 min 12.5 [11.5–13.5] 13.5 [11.2–14.3] 13.7 [10.6–14.8] 9.0 [7.0–10.6]
60 min 5.7 [4.3–6.6] 5.8 [5.1–6.4] 5.7 [5.3–6.1] NA
Friedman-Test p <0.001a <0.001a <0.001a 0.12
Linear regression with clustered robust SE p = 1.000
(Coef. helium: 0.06 CI −1.55 to 1.67; Coef. argon: 0.04 CI −1.63 to 1.70)
Time effect: fractional polynomial regression p < 0.001
Lactatea [mmol/l] Baseline (Before) 1.2 [0.9–1.3] 1.2 [1.0–1.7] 1.1 [1.0–1.5] p = 0.72 1.0 [0.9–1.4]
5 min 7.0 [6.4–7.5] 7.2 [6.1–8.2] 6.8 [6.3–8.0] 1.0 [0.6–1.2]
15 min 3.5 [3.2–3.8] 3.2 [3.0–3.9] 3.6 [3.0–4.4] 0.9 [0.6–1.8]
60 min 0.8 [0.6–1.2] 0.7 [0.6–0.8] 0.7 [0.6–0.8] NA
Friedman-Test p <0.001a <0.001a <0.001a 0.531
Linear regression with clustered robust SE p = 0.771
(Coef. helium: 0.38 CI −0.81 to 1.57; Coef. argon: −0.04 CI −0.56 to 0.48)
Time effect: fractional polynomial regression p < 0.001
pHa Baseline (Before) 7.50 [7.45–7.53] 7.50 [7.45–7.54] 7.42 [7.40–7.49] p = 0.17 7.41 [7.37–7.51]
5 min 7.09 [7.01–7.15] 7.02 [6.96–7.10] 7.09 [6.98–7.16] 7.44 [7.36–7.47]
15 min 7.24 [7.16–7.28] 7.16 [7.08–7.26] 7.30 [7.10–7.31] 7.45 [7.347–7.49]
60 min 7.38 [7.32–7.44] 7.35 [7.30–7.39] 7.39 [7.33–7.41] NA
Friedman-Test p <0.001a <0.001a <0.001a 0.967
Linear regression with clustered robust SE p = 0.631
(Coef. helium: 0.11 CI −0.37 to 0.15; Coef. argon: −0.02 CI −0.08 to 0.05)
Time effect: fractional polynomial regression p = 0.037
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gases and the air rats (details see Table 3). Only few
injured neurons could be seen in the cortex in the FJB
(picture 2 E and F). This due to the uneven distribution of
neuronal injury after hypoxia, where the neurons of the
CA1 layer are considered as the most vulnerable neurons
throughout the brain [38, 39].
Discussion
In our model of 8 min cardiac arrest, the animals suf-
fered from a considerable hypoxic-ischemic event,
demonstrated by the important delays for executing
the neurobehavioral tasks (Table 2) and the extensive
damage in the histological examinations (Table 3).
The exposure to helium or argon in 50 % oxygen for
24 h did not ameliorate the extent of the damage: we
did not find any significant statistical differences in
the neurobehavioral tests and in Fluoro-Jade B stain-
ing. In the cresyl violet staining, the histological ana-
lysis tends towards less damaged cells in the CA1
segment of the hippocampus in the noble gas groups
(helium better than argon), resulting in a more pre-
served cell layer of the CA1 segment. Looking at the
entire cell layer breadth though, argon treated animals
have more preserved cells than the rats in the helium
group, which is unexpected, regarding the cell count
in the resyl violet staining. We believe this difference
is based on the difficulties to delineate the borders of
the curved CA1 segment exactly in plane microscopy
pictures.
Our results are not in line with those recently pub-
lished by Brücken et al. and by Ristagno et al. in regard
of the neuroprotective properties of argon [24, 26, 27],
which could be explained by some differences in the ex-
periment settings. In Brücken’s group, the rats sustained
a shorter cardiac arrest (7 min vs 8 min in our experi-
ments), but the time from induction of CA to ROSC
was about 645 s in their study, compared with 540 [IQR
529 to 560] seconds, a considerable difference in total
ischemia time, which might results in a more severe
damage. This is further supported by the fact, that
Table 1 Hemodynamic data and blood gas analysis (Continued)
pO2 [mmHg] Baseline (Before) 114 [106–124] 114 [101–132] 106 [83–139] p = 0.83 83 [74–97]
5 min 203 [146–246] 155 [127–250] 195 [265–355] 332 [270–342]
15 min 125 [101–159] 109 [105–143] 129 [118–165] 240 [90–324]
60 min 159 [136–185] 140 [128–181] 195 [182–212] NA
Friedman-Test p 0.007a <0.001a <0.001a 0.236
Linear regression with clustered robust SE p = 0.373
(Coef. helium: −45.5 CI −114.2 to 23.2; Coef. argon: −48.8 CI −118.9 to 21.3)
Time effect: fractional polynomial regression p = 0.670
pCO2
a [mmHg] Baseline (Before) 32 [29–37] 31 [27–35] 37 [27–39] p = 0.69 34 [32–42]
5 min 46 [38–66] 53 [40–66] 46 [37–52] 35 [32–43]
15 min 39 [36–53] 44 [35–62] 36 [32–46] 36 [30–43]
60 min 39 [34–47] 41 [35–49] 35 [31–39] NA
Friedman-Test p 0.002a 0.003a 0.013a 0.335
Linear regression with clustered robust SE p = 0.741
(Coef. helium: 2.07 CI −6.03 to 10.17; Coef. argon: 3.40 CI −5.80 to 12.59)
Time effect: fractional polynomial regression p < 0.001
Temp. [°C] Baseline (Before) 36.0 [35.7–36.2] 36.4 [36.1–36.5] 36.0 [35.8–36.2] p = 0.07 36.0 [35.8–37.1]
5 min 35.3 [35.0–35.4] 35.0 [34.8–35.6] 35.3 [34.7–35.6] 36.5 [36.0–36.9]
15 min 36.2 [36.0–36.3] 36.2 [35.8–36.2] 36.2 [36.0–36.6] 36.4 [36.1–36.6]
60 min 36.8 [36.3–37.4] 36.6 [36.4–37.2] 37.0 [36.7–37.3] NA
Friedman-Test p <0.001a <0.001a 0.002a 0.967
Linear regression with clustered robust SE p = 0.378
(Coef. helium: 0.42 CI −0.54 to 1.37; Coef. argon: −0.84 CI −2.46 to 0.77)
Time effect: fractional polynomial regression p = 0.487
Comparisons of baseline parameters were calculated with the Kruskal-Wallis ANOVA on Ranks. Differences between the groups were computed with a linear regression with
clustered robust SE, time effect with fractional polynomial regression. The animals in the non-ischemic sham group were not randomized, and thus indicated in italic style.
These animals are not included in the main statistical analysis. The post-hoc Kruskall Wallis and Friedman tests were performed to compare groups at baseline and the time
effect within the groups, but should be interpreted with caution (see text). Data are given as median and [interquartile ranges]
a denotes significant time effects
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Table 2 Results of neurobehavioral tests
Helium/oxygen Argon/oxygen Air/oxygen Kruskall - Wallis Non-ischemic sham
Weighta [g] Baseline (Before) 358 [343–383] 343 [334–367] 345 [326–372] p = 0.375 400 [375–413]
Day 1 342 [328–367] 335 [314–361] 339 [322–360] 384 [360–409]
Wilcoxon Test p 0.01 <0.01 0.02 0.04
Day 2 338 [322–354] 323 [306–351] 323 [304–345] 389 [365–404]
Day 3 342 [327–362] 327 [306–355] 330 [308–343] 391 [361–408]
Day 4 339 [327–372] 329 [309–365] 328 [313–345] 400 [369–410]
Day 5 348 [324–380] 341 [319–370] 332 [318–355] 401 [374–415]
Friedman-Test p <0.001a <0.001a <0.001a <0.001a
Linear regression with clustered robust SE p = 0.302
(Coef. helium: −11.9 CI −33.0 to 9.2; Coef. argon: −15.2 CI −36.1 to 5.6)
Time effect: fractional polynomial regression p = 0.001
Tape Removal Testa [seconds] Baseline (Before) 18 [11–29] 9 [5–12] 13 [8–23] p = 0.06 17 [14–39]
Day 1 74 [21–120] 120 [35–120] 85 [23–120] 10 [8–21]
Wilcoxon Test p 0.01 <0.01 <0.01 0.38
Day 2 21 [12–76] 18 [11–111] 17 [9–120] 14 [7–18]
Day 3 20 [8–113] 16 [11–120] 31 [9–88] 18 [15–95]
Day 4 14 [10–113] 11 [7–59] 17 [9–120] 19 [7–96]
Day 5 12 [7–45] 9 [5–44] 11 [7–93] 12 [7–17]
Friedman-Test p 0.018a 0.002a 0.023a 0.086
Linear regression with clustered robust SE p = 0.980
(Coef. helium: −2.01 CI −35.88 to 31.86; Coef. argon: −3.24 CI −36.49 to 30.01)
Time effect: fractional polynomial regression p < 0.001
Neuro Deficit Scorea [range: 0–100] Baseline (Before) 0 [0–0] 0 [0–0] 0 [0–0] p = 0.37 0 [0–0]
Day 1 2.5 [0–3.0] 3.0 [0.5–3.0] 2.5 [0.5–3.0] 0 [0–0]
Wilcoxon Test p 0.02 0.02 0.03 1.0
Day 2 0 [0–2.3] 0 [0–2.0] 0 [0–1.5] 0 [0–0]
Day 3 0 [0–0.3] 0 [0–1.3] 0 [0–0.5] 0 [0–0]
Day 4 0 [0–0.3] 0 [0–0.5] 0 [0–0] 0 [0–0]
Day 5 0 [0–0.3] 0 [0–0.3] 0 [0–0] 0 [0–0]
Friedman-Test p <0.001a <0.001a <0.001a 1.0
Linear regression with clustered robust SE p = 0.612
(Coef. helium: 0.50 CI −0.68 to 1.69; Coef. argon: 0.35 CI −0.63 to 1.32)
Time effect: fractional polynomial regression p < 0.001
Vertical Pole Testa [range: 0–3] Baseline (Before) 0 [0–0] 0 [0–0] 0 [0–0] p = 0.60 0 [0–0]
Day 1 2.5 [0.25–3.0] 3.0 [1.0–3.0] 2.5 [1.5–3.0] 0 [0–0]
Wilcoxon Test p 0.03 0.02 0.03 1.0
Day 2 0 [0–2.0] 0 [0–1.5] 0 [0–1.0] 0 [0–0]
Day 3 0 [0–0] 0 [0–1.0] 0 [0–0] 0 [0–0]
Day 4 0 [0–0] 0 [0–0] 0 [0–0] 0 [0–0]
Day 5 0 [0–0] 0 [0–0] 0 [0–0] 0 [0–0]
Friedman-Test p <0.001a <0.001a <0.001a 1.0
Linear regression with clustered robust SE p = 0.663
(Coef. helium: 0.15 CI −0.34 to 0.64; Coef. argon: 0.21 CI −0.32 to 0.75)
Time effect: fractional polynomial regression p < 0.001
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Brücken’s animals were more severely impaired in the
neuropsychological testing. As for the pigs used in the
Ristagno’s experiment, the time period until return of a
stable circulation was even longer, with a combined no-
flow and low-flow time of 817 s. Further differences
affect the argon application: Brücken used a 70 % argon
in oxygen mixture and started 60 min post ROSC, the
argon was applied for 60 min. Ristagno also used 70 %
argon in oxygen, but started 5 min after ROSC and con-
tinued for 4 h. The rational for administering 50 % argon
Table 2 Results of neurobehavioral tests (Continued)
Open Field Test: distancea [cm] Baseline (Before) 1691 [1327–1900] 1769 [1620–2101] 1580 [1520–1951] p = 0.23 1693 [1378–1938]
Day 4 1673 [1161–1919] 1320 [1144–1712] 2058 [1698–2403] 1034 [799–1698]
Day 5 851 [758–1343] 1240 [658–1606] 962 [711–1629] 774 [698–1196]
Friedman-Test p 0.06 0.07 0.24 0.02a
Linear regression with clustered robust SE p = 0.156
(Coef. helium: −244 CI −528 to 39; Coef. argon: −5 CI −465 to 455)
Time effect: fractional polynomial regression p = 0.002
Open Field Test: mobility/immobility
ratioa [%]
Baseline (Before) 82 [77–88] 88 [81–92] 84 [82–87] p = 0.24 83 [80–85]
Day 4 81 [71–84] 81 [75–88] 85 [82–87] 65 [54–84]
Day 5 59 [51–72] 77 [50–86] 67 [46–82] 56 [41–65]
Friedman-Test p 0.15 0.20 0.06 <0.01a
Linear regression with clustered robust SE p = 0.112
(Coef. helium: −4.63 CI −11.87 to 2.62; Coef. argon: 2.51 CI −6.22 to 11.24)
Time effect: fractional polynomial regression p < 0.001
Open Field Test: extern/intern
ratioa [%]
Baseline (Before) 94 [93–96] 94 [93–96] 96 [94–97] p = 0.84 96 [93–98]
Day 4 99 [97–100] 98 [96–99] 95 [95–97] 100 [97–100]
Day 5 100 [99–100] 99 [99–100] 99 [95–100] 100 [98–100]
Friedman-Test p 0.02a 0.03a 0.03a 0.03a
Linear regression with clustered robust SE p = 0.501
(Coef. helium: 0.68 CI −1074 to 2.10; Coef. argon: 0.33 CI −1.55 to 2.22)
Time effect: fractional polynomial regression p = 0.003
Open Field Test: rears/verticala
[count]
Baseline (Before) 15 [12–23] 20 [19–23] 19 [16–22] p = 0.21 17 [14–22]
Day 4 6 [5–8] 5 [3–10] 8 [5–9] 9 [7–13]
Day 5 3 [1–4] 6 [2–9] 4 [2–7] 7 [4–9]
Friedman-Test p <0.001a <0.001a <0.001a <0.001a
Linear regression with clustered robust SE p = 0.107
(Coef. helium: −2.73 CI −5.58 to 0.11; Coef. argon: −0.40 CI −4.13 to 3.33)
Time effect: fractional polynomial regression p < 0.001
Comparisons of baseline were calculated with the Kruskal-Wallis ANOVA on ranks. Differences between the groups were computed with a linear regression with
clustered robust SE, time effect with fractional polynomial regression. The animals in the non-ischemic sham group were not randomized, and thus indicated in
italic style. These animals are not included in the main statistical analysis. The post-hoc Kruskall Wallis; Wilcoxon and Friedman tests were performed to compare
groups at baseline and the time effect within the groups, but should be interpreted with caution (see text). Data are given as median and [interquartile ranges]
a denotes significant time effects
Table 3 Histomorphometry of the hippocampus CA1 segment on day 5
Helium/oxygen Argon/oxygen Air/oxygen Kruskall - Wallis Non-ischemic sham
Fluoro-Jade [numbers of stained cells per mm] 148 [140–166] 154 [124–199] 145 [138–182] p = 0.83 0 [0–0]
pyknotic cells in CA1 [%] 53 [24–76] 59 [44–86] 80 [61–93] p = 0.09 0 [0–1]
CA1 cell layer atrophy (normalized: surface/length)
[mm2/mm]
0.065 [0.058–0.083] 0.074 [0.061–0.080] 0.061 [0.043–0.069] p = 0.11 0.082 [0.077–0.088]
Histological assessment of the hippocampus CA1 segment on day 5 shows a substantial damage after cardiac arrest, but there were no differences between the
resuscitated animals. The animals in the non-ischemic sham group were not randomized, and thus indicated in italic style. These animals are not included in the
main statistical analysis
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early after the insult in our protocol is based on the
work by David et al. [20] and Loetscher et al. [18], both
found a maximum neuroprotective effect with a 50 %
argon 25 % oxygen 25 % nitrogen gas mix. Increasing
the argon concentration beyond 50 % reduced the suc-
cess of neuroprotection in their experiments. Ryang et
al. [23] also used 50 % argon 50 % oxygen mix in their
model of transient middle cerebral artery occlusion
(MCAO), where an important reduction of neuronal
damage could be detected.
Different timing of argon application might be important
too: Ryang administered the argon during ischemia and be-
fore reperfusion [23] and David used a similar approach in
the in vivo experiments [20]. Brücken found a significant
effect even after a delayed administration of 3 h [26].
Loetscher subjected hippocampal neurons to delayed argon
treatment and found a time-dependent reduction of efficacy
[18]. Based on these results, we administered the noble
gases early after cardiac arrest and thus expected a signifi-
cant improvement.
Another significant difference between these above men-
tioned studies affects the duration of gas administration. In
our experiment we had a long exposure for 24 h compared
to 1 h (Brücken), respective 4 h (Ristagno).
We are unaware of negative effects of prolonged helium
or argon administration, and the positive effects found by
Loetscher et al. were produced with a 3-day incubation
period of the hippocampal slices [18]. Generally, mechan-
ical ventilation with a helium/oxygen mixture (Heliox) is
regarded as safe and is used since 1934 without negative
effects [40].
With regard to histology, the differences between our re-
sults and the results of Brücken need to be mentioned. The
hippocampus CA1 region is considered as the most vulner-
able area of the brain after hypoxic ischemic injury [38]. As
expected, in the Brücken experiments most damage could
be found in this specific region, with a neuronal damage
index of about 3 (from 0 to 11; 0 indicating no damage, 11
indicating complete destruction) in both (air and argon)
groups. The statistically significant difference in neuronal
damage between the animals in the air and argon groups
were discovered in the less vulnerable neocortex areas and
in the CA3/4 segment of the hippocampus with a neur-
onal damage index of about 1.0 in the air group and 0.7 in
the argon group, but there were no significant differences
within the CA1 segment between the groups. In a further
publication of the model, the CA1 region was even not re-
ported [25, 26]. Different impact of argon neuroprotection
between cortex and subcortical areas has also been de-
scribed elsewhere [20].
Helium as a neuroprotective agent is less investigated
and the results are ambiguous: some authors did not
find any [14] or only minor positive effects [21], others
reported significant positive effects in in vitro experiments
Fig. 2 Examples of Fluoro-Jade B staining of the hippocampus.
Overview of the hippocampus (a and c) and close-up view of the CA1
region (b) and (d) of a sham animal without cardiac arrest (a and b) and
of an animal with cardiac arrest (c and d). Compared to the animal with
surgery only, FJB staining (indicating degenerating neurons, white
arrowheads) was prominently present in the CA1 region, with
occasionally positive cells scattered throughout the hilus region. A few
dispersed cells (white arrowheads) are found in the cortex of animals with
cardiac arrest stain positive for FJB (e, overview and f, close-up view)
Fig. 3 Examples of Cresyl Violet staining of the hippocampus CA1
segment. Overview of the hippocampus (a and b) and close-up
view of the CA1 region (c) and (d) of a sham animal without cardiac
arrest (a and c) and of an animal with cardiac arrest and argon
treatment (b and d). Arrowheads show pyknotic cells, indicating
apoptosis in the animal which suffered from cardiac arrest
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[17], whilst other studies found even detrimental effects
[19]. In vivo, exposure to helium reduced infarct volume
in a rat MCAO model [41] as well as in a model inflicting
moderate hypoxic-ischemic brain injury in rat pups [21]. It
has been discussed whether these discrepant findings could
be explained by compressed helium-induced hypothermia,
because helium possesses a high heat-transfer capacity. In a
study where helium was warmed up, no neuroprotective
capacity could be detected [42].
Limitations of our study include the small numbers of
animals per group, which decreases the potential to detect
a small difference. This argument is especially important
for negative trials at risk for type II errors, when an under-
powered study concludes a possible helpful intervention
as unusable. A post-hoc sample size calculation with the
(false) assumption of normal distribution would indicate a
group size of 44 animals per group to detect a 20 % differ-
ence in pyknotic cells in the cresyl violet staining and a
group size of 114 animals per group for a 20 % difference
in the FJB staining (with a power of 0.8 and an alpha of
0.05). The wide confidence intervals in the regression
analysis of the neurobehavioral data and the aforemen-
tioned post-hoc sample size calculation of the histology
assessments data make the possibility of rendering the
study “positive” simply by increasing the numbers of
animals improbable.
Temperature management could also be a relevant
issue. It can be argued that the baseline temperature be-
fore cardiac arrest was not exactly the same (without stat-
istical significance). In the argon group we observed a
more prominent temperature drop at 5 min post ROSC
without being statistically significant comparing to the
other groups. And given that hypothermia is neuroprotec-
tive, we would have expected a better outcome in the
argon group, which was not the case in the present study.
The neurobehavioural tests we used can be criticized
as not sensitive enough to detect small but significant
differences in a cardiac arrest model. So the neurodeficit
score ranges from 0 to 100 (with 100 indicating brain
death), and the median value at day 1 was 5 in the argon
group, indicating rather mildly affected animals after
resuscitation. The dorso-septal pole of the hippocampus
in rats is responsible for spatial learning. Performing
different tests, e.g. a water-maze or novel object location
test [43] might be better tests for testing the damage in
this area; with the limitation of a more difficult inter-
pretation of these tests due to different behavioral pat-
terns depending on age after cardiac arrest [44].
Brain regions other than the hippocampus CA1 segment
have not been examined in detail. As shown as an ex-
ample in Fig. 2 in the dentate gyrus (2 C) or cortex (2 E
and F), other regions of the brain show only minimal
neuronal degeneration, a finding consistent with the litera-
ture [38]. Quantification and group comparison of these
minimal changes are unlikely to provide reliable statistical
data because of the wide dispersal of their numbers.
In this series we have not added immunostaining to
elucidate the pathway of neuronal degeneration. We
cannot prove that the predominant form of neuronal
degeneration is apoptosis because we have not per-
formed staining for Caspase-3 or TUNEL. We know
from former experiments that no signs of cell death can
be found on day 2 [28], which is an indicator of delayed
cell death/apoptosis.
Conclusion
In conclusion, treatment with neither argon nor helium
improved functional outcome or reduced neuronal dam-
age in the most vulnerable part of the brain (hippocampal
CA1 region) after 8 min of cardiac arrest. In contrast to
in-vitro experiments, helium does not seem to exhibit
neuroprotective properties in rats. The population which
might profit from noble gas exposure after cardiac arrest,
as well as the protocol of administration (timing, duration,
concentration), needs to be further characterized.
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